1202402-40-1 Usage
Description
(S)-7-(5-Methyl-furan-2-yl)-3-[6-(tetrahydro-furan-3-yloxyMethyl)-pyridin-2-ylMethyl]-3H-[1,2,3]triazolo[4,5-d]pyriMidin-5-ylaMine is a complex organic compound with a unique molecular structure. It is characterized by its tricyclic ring system, which includes a triazolopyrimidine core, a methylfuran and a pyridinyl group. (S)-7-(5-Methyl-furan-2-yl)-3-[6-(tetrahydro-furan-3-yloxyMethyl)-pyridin-2-ylMethyl]-3H-[1,2,3]triazolo[4,5-d]pyriMidin-5-ylaMine is of interest due to its potential applications in various fields, particularly in the pharmaceutical industry.
Uses
Used in Pharmaceutical Industry:
(S)-7-(5-Methyl-furan-2-yl)-3-[6-(tetrahydro-furan-3-yloxyMethyl)-pyridin-2-ylMethyl]-3H-[1,2,3]triazolo[4,5-d]pyriMidin-5-ylaMine is used as a pharmaceutical compound for its potential therapeutic properties. The compound's unique structure may allow it to interact with specific biological targets, making it a candidate for the development of new drugs.
Used in Research and Development:
In the field of research and development, this compound can be used as a starting material or a building block for the synthesis of more complex molecules with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science.
Used in Drug Design and Optimization:
The unique structure of (S)-7-(5-Methyl-furan-2-yl)-3-[6-(tetrahydro-furan-3-yloxyMethyl)-pyridin-2-ylMethyl]-3H-[1,2,3]triazolo[4,5-d]pyriMidin-5-ylaMine makes it a valuable tool in drug design and optimization. Researchers can use this compound to explore new chemical space and develop novel therapeutic agents with improved efficacy and selectivity.
Used in Chemical Synthesis:
(S)-7-(5-Methyl-furan-2-yl)-3-[6-(tetrahydro-furan-3-yloxyMethyl)-pyridin-2-ylMethyl]-3H-[1,2,3]triazolo[4,5-d]pyriMidin-5-ylaMine can also be used as an intermediate in the synthesis of other complex organic molecules. Its unique functional groups and structural features make it a versatile building block for the preparation of a wide range of compounds with diverse applications.
in vivo
Daily treatment of the syngeneic mouse model MC38 with CPI-444 (1, 10, 100 mg/kg) leads to dose-dependent inhibition of tumor growth, leading to tumor elimination in ~30% of treated mice. Combining CPI-444 (100 mg/kg, qd, 14 days) with anti-PD-L1 (200 μg, 3qw, 4 doses) treatment in MC38 models synergistically inhibits tumor growth and eliminates tumors in 90% of treated mice. When cured mice are later re-challenged with MC38 cells, tumor growth is rejected in 100% of challenged mice, indicating that CPI-444 induces systemic anti-tumor immune memory.
Biological Functions
CPI-444 is a small molecule, oral, checkpoint inhibitor designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of adenosine in the tumor microenvironment to the A2A receptor. Adenosine, a metabolite of ATP (adenosine tri-phosphate), is produced within the tumor microenvironment where it may bind to the adenosine A2A receptor present on immune cells and block their activity. CD39 and CD73 are enzymes on the surface of tumor cells and immune cells. These enzymes work in concert to convert ATP to adenosine. In vitro and preclinical studies have shown that dual blockade of CD73 and the A2A receptor may be synergistic.
in vitro
CPI-444 is a potent, oral, selective A2AR antagonist. CD8+ T cell depletion abrogates the efficacy of CPI-444 treatment as a single agent as well as in combination with anti-PD-L1, demonstrating a role for CD8+ T cells in mediating primary and secondary immune responses. Anti-tumor efficacy of CPI-444±anti-PD-L1 is associated with increased CD8+ cell infiltration and activation in MC38 tumor tissues, and a corresponding rise in PD-1 expression on CD8+ T cells in the spleen. Additionally, levels of immune checkpoints are modulated by treatment with CPI-444, including GITR, OX40, and LAG3 on tumor infiltrating lymphocytes and circulating T cells, suggesting a broad role for adenosine mediated immunosuppression.
References
1) Willingham?et al.?(2018),?A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti-PD-(L)1 and Anti-CTLA-4 in Preclinical Models;?Cancer Immunol. Res.?6?1136
2) Leone?et al.?(2018),?), Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models;?Cancer Immunol. Immunother.?671271
3) NCT02655822
Check Digit Verification of cas no
The CAS Registry Mumber 1202402-40-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,0,2,4,0 and 2 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1202402-40:
(9*1)+(8*2)+(7*0)+(6*2)+(5*4)+(4*0)+(3*2)+(2*4)+(1*0)=71
71 % 10 = 1
So 1202402-40-1 is a valid CAS Registry Number.
1202402-40-1Relevant articles and documents
PROCESSES FOR MAKING TRIAZOLO [4,5D] PYRAMIDINE DERIVATIVES AND INTERMEDIATES THEREOF
-
, (2020/05/12)
Provided herein are, inter alia, methods for making triazolo [4,5] pyramidine derivatives and intermediates. The compounds described herein can be used for the preparation of pharmaceutical compositions, including the compounds of formulae (I), (II), (III), or (IV) for the treatment of diseases, including cancer. The provided compositions are, inter alia, suitable for formulation and administration in vitro or in vivo.
TRIAZOLO [4, 5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS
-
Page/Page column 30-31, (2010/01/30)
Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are. disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.
